Positive results from third and final pivotal Phase 3 study of brodalumab in patients with moderate-to-severe plaque psoriasis were announced recently.
Amgen and AstraZeneca have announced that AMAGINE-2(TM), a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara(®) (ustekinumab) and placebo at week 12.
Brodalumab 210 mg given every two weeks and the brodalumab weight-based analysis group were each shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75).
Dr Nitin Ranjan
Latest posts by Dr Nitin Ranjan (see all)
- Skin-whitening with Glutathione: is it safe? - June 29, 2016
- What’s the difference between hair color & hair dye? - March 31, 2015
- AIDS & HIV: what everyone should know - February 19, 2015
